What labs are elevated in sickle cell?

What Does My Result Mean?

Positive result: Indicates that the screening test detected the presence of Hemoglobin S or sickle hemoglobin, which may mean you carry the sickle cell trait. These results are a preliminary screening. The Red Cross recommends that you consult your medical provider to discuss your test results and pursue additional testing. Those who receive a positive result will also receive a letter in the mail.

It is important to note that carrying the sickle cell trait does not mean that an individual has sickle cell disease. In general, individuals who carry the sickle cell trait have no medical conditions related to sickle cell disease.

Negative result: Indicates that the screening test did not detect the presence of Hemoglobin S or sickle hemoglobin. This means that the individual is likely not a sickle cell trait carrier. It is important to note that the Red Cross is not screening for other abnormal hemoglobin cells that can also cause sickling, such as Hemoglobin. If you have a family history of other hemoglobin conditions, you may want to consult your medical provider.

Inconsistent result: Indicates that the Red Cross is unable to confirm a positive or negative screening result. In some cases, this is because the Red Cross testing laboratory may have previously screened a donor for sickle cell trait at a hospital request to fulfill a specific product need for a patient. In some cases, the donor may have received a prior notification of a positive result. While the Red Cross will work to resolve many inconsistent results, a portion may remain inconsistent.

Not Tested result: While rare, some donations may not be able to be tested due to processing issues. Donors will need to have a successful donation to receive sickle cell trait screening results. Per standard procedures, only successful donations are sent to our laboratory for testing.

1. Stypulkowski J.B., Manfredini V. Changes in hemostasis in sickle cell disease patients. Rev Bras Hematol Hemoter. 2010;32(1):56–62. [Google Scholar]

2. Di Nuzzo D.V., Fonseca S.F. Anemia falciforme e infecções. J Pediatr (Rio J) 2004;80(5):347–354. [PubMed] [Google Scholar]

3. Galiza Neto G.C., Pitombeira M.d.S. Aspectos moleculares da anemia falciforme. J Bras Patol Med Lab. 2003;39(1):51–56. [Google Scholar]

4. Embury S., Bennett J., Plum F. 20a ed. Guanabara Koogan; Rio de Janeiro: 1997. Cecil tratado de medicina interna. [Google Scholar]

5. Costa F.F., Fertrin K.Y. Sickle cell anemia. Springer International Publishing; 2016. Clinical manifestations and treatment of adult sickle cell disease; pp. 285–318. [Google Scholar]

6. Serjeant G.R. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3(10):a011783. [PMC free article] [PubMed] [Google Scholar]

7. ANVISA . ANVISA; Brasília: 2001. Manual de Diagnóstico e Tratamento de Doenças Falciformes. [Google Scholar]

8. Rodgers G.P. 2015. Hydroxyurea and other disease-modifying therapies in sickle cell disease. UpToDate. Available from: http://www.uptodate.com/contents/hydroxyurea-and-other-disease-modifying-therapies-in-sickle-cell-disease [cited 21.03.16] [Google Scholar]

9. Brasil . 2010. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas – Doença Falciforme. Porteria SAS/MS n° 55, de 29 de janeiro de. [Google Scholar]

10. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322. [PubMed] [Google Scholar]

11. Loureiro M.M., Rozenfeld S. Epidemiologia de internações por doença falciforme no Brasil. Rev Saúde Pública. 2005;39(6):943–949. [PubMed] [Google Scholar]

12. Brasil . Ministério da Saúde; Brasília: 2012. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada. Doença falciforme: Condutas básicas para tratamento. Departamento de Atenção Especializada. [Google Scholar]

13. Brasil . 1 ed., 1. reimpr. Ministério da Saúde; Brasília: 2014. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Hospitalar e de Urgência. Doença falciforme: Hidroxiureia: uso e acesso/Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Hospitalar e de Urgência. [Google Scholar]

14. Felix A.A., Souza H.M., Ribeiro S.B.F. Aspectos epidemiológicos e sociais da doença falciforme. Rev Bras Hematol Hemoter. 2010;32(3):203–208. [Google Scholar]

15. Watanabe A.M., Pianovski M.A., Neto J.Z., Lichtvan L.C., Chautard-Freire-Maia E.A., Domingos M.T. Prevalência da hemoglobina S no Estado do Paraná, Brasil, obtida pela triagem neonatal. Cad Saúde Pública. 2008;24(5):993–1000. [PubMed] [Google Scholar]

16. Gumiero A.P., Bellomo-Brandão M.A., Costa-Pinto E.A. Gallstones in children with sickle cell disease followed up at a Brazilian hematology center. Arq Gastroenterol. 2008;45(4):313–318. [PubMed] [Google Scholar]

17. Walker T.M., Hambleton I.R., Serjeant G.R. Gallstones in sickle cell disease: observations from The Jamaican Cohort study. J Pediatr. 2000;136(1):80–85. [PubMed] [Google Scholar]

18. Duncan N., Tennant I., Crawford-Sykes A., Barnett A., Scarlett M., Dundas S. Open splenectomy in Jamaican children with sickle cell disease. West Indian Med J. 2006;55(1):37–41. [PubMed] [Google Scholar]

19. Topley J.M., Rogers D., Stevens M., Serjeant G.R. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child. 1981;56(10):765–769. [PMC free article] [PubMed] [Google Scholar]

20. Passos V.M., Assis T.D., Barreto S.M. Hipertensão arterial no Brasil: estimativa de prevalência a partir de estudos de base populacional. Epidemiol Serv Saúde. 2006;15(1):35–45. [Google Scholar]

21. Bunn H.F., Nathan D.G., Dover G.J., Hebbel R.P., Platt O.S., Rosse W.F. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687–692. [PubMed] [Google Scholar]

22. Lobo C., Marra V.N., Silva R.M. Crises dolorosas na doença falciforme. Rev Bras Hematol Hemoter. 2007;29(3):247–258. [Google Scholar]

23. David R.C., Moraes Júnior H.V., Rodrigues M.P. Alterações oculares e eletrorretinográficas na doença falciforme. Arq Bras Oftalmol. 2011;74(3):190–194. [PubMed] [Google Scholar]

24. Gualandro S.F., Fonseca G.H., Gualandro D.M. Complicações cardiopulmonares das doenças falciformes. Rev Bras Hematol Hemoter. 2007;29(3):291–298. [Google Scholar]

25. Silva-Pinto A.C., Angulo I.L., Brunetta D.M., Neves F.I., Bassi S.C., Santis G.C. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Sao Paulo Med J. 2013;131(4):238–243. [PubMed] [Google Scholar]

26. Bandeira F., Peres J.C., Carvalho E.J., Bezerra I., Araújo A.S., Mello M. Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife-PE. Rev Bras Hematol Hemoter. 2004;26(3):189–194. [Google Scholar]

Page 2

Clinical characteristics of 50 patients with sickle cell anemia.